Key points are not available for this paper at this time.
Immunogenic cell death (ICD) is a way of reengaging the tumor-specific immune system. ICD can be induced by treatment with chemotherapeutics. However, only a limited number of drugs and other treatment modalities have been shown to elicit the biomarker responses characteristic of ICD and to provide an anticancer benefit in vivo. Here, we report a rationally designed redox-active Au(I) bis-N-heterocyclic carbene that induces ICD both in vitro and in vivo. This work benefits from a synthetic pathway that allows for the facile preparation of asymmetric redox-active Au(I) bis-N-heterocyclic carbenes.
Building similarity graph...
Analyzing shared references across papers
Loading...
Sajal Sen
Stephanie Hufnagel
Esther Y. Maier
Journal of the American Chemical Society
The University of Texas at Austin
Wright State University
Building similarity graph...
Analyzing shared references across papers
Loading...
Sen et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d7c0e7ae371f9756ae2a9c — DOI: https://doi.org/10.1021/jacs.0c09753
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: